Jasper Therapeutics Inc
Change company Symbol lookup
Select an option...
JSPR Jasper Therapeutics Inc
JPM JPMorgan Chase & Co
UVV Universal Corp
LNC Lincoln National Corp
FMCCG Federal Home Loan Mortgage Corp
CSAN Cosan SA
SAIC Science Applications International Corp
MUR Murphy Oil Corp
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
CODI Compass Diversified Holdings
Go

Company profile

Jasper Therapeutics, Inc., formerly Amplitude Healthcare Acquisition Corporation, is a biotechnology company focused on hematopoietic cell transplant therapies. The Company has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The Company also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.

Closing Price
$4.36
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.66
Day's Low
4.25
Volume
(Light)
Volume:
51,421

10-day average volume:
92,762
51,421

Company Profile

Jasper Therapeutics, Inc., formerly Amplitude Healthcare Acquisition Corporation, is a biotechnology company focused on hematopoietic cell transplant therapies. The Company has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The Company also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
2.10x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

January 2022
Current Month
439.7K
Previous Month
490.8K
Percent of Float
2.98%
Days to Cover
5.1537 Days

Share Information

JSPR is in a share class of common stock
Float
12.3M
Shares Outstanding
37.9M
Institutions Holding Shares
17
38.85%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.